secwatch.observer — SEC 8-K summary ====================================== Issuer: STANDARD BIOTOOLS INC. (LAB) CIK: 0001162194 Form: 8-K Filed at: 2026-11-19T22:00:02+00:00 Accession: 0001140361-26-044934 Event type: m_and_a Sentiment: positive Materiality: 0.65 Item codes: 5.02, 5.07, 7.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 Standard BioTools holders approve Treeline merger, reverse split up to 1-for-40, Mass Cytometry sale -------------------------------------------------------------------------------- - All seven special-meeting proposals passed; share issuance for the Treeline Biosciences merger won 274,099,041 votes for vs 7,571,806 against. - Charter amendment approved to effect a reverse split of 1-for-20 to 1-for-40, ratio to be mutually agreed with Treeline, and rename the company Treeline Biosciences, Inc. - Element Mass Cytometry divestiture to Element Biosystems, LLC (a GMT Venture Partners vehicle) approved 276,299,544 to 5,336,020. - Quorum of 281,744,412 votes, about 71.38% of the 394,711,296 shares outstanding as of the October 16, 2026 record date; no broker non-votes. - Treeline merger expected to close in Q4 2026, with the Mass Cytometry sale closing substantially concurrently; CEO Michael Egholm called the votes an important step. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000114036126044934/0001140361-26-044934-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1162194/000114036126044934/ef20085888_8k.htm HTML page: https://secwatch.observer/filing/0001140361-26-044934 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer